WHITE PAPER ON NATIONAL TRANSPORT POLICY

whitePaper | February 12, 2020

Both the U.S. Government and biopharmaceutical industry have been central engines for developing new medical treatments and cures, thereby lowering the effective price of better health for patients worldwide. The sector has done so by being both the world leader in these biopharmaceutical cures and treatments as well as the source of the returns that are required to fund new medical R&D investments.

whitePaper | November 5, 2019

This final report of the Taskforce on Transforming the Economic Dimension of U.S. China Strategy outlines a four-part strategy for an effective U.S. response to the economic challenges presented by China.

whitePaper | March 13, 2023

The intensifying impacts of climate change create challenges for the environment, public health, and the economy. President Biden set an ambitious target for the United States to achieve a 50-52 percent reduction in annual greenhouse gas emissions1 from 2005 levels by 2030, and is mobilizing a whole-of-government approach to climate action, capitalizing on major legislative achievements, through policies in the 2024 fiscal year budget that hasten and smooth the transition to a net-zero economy.

whitePaper | March 30, 2022

Why have we written disparaging statements about government when our firm is so deeply committed to public sector excellence? These include statements like “as the fire rages on, our governments seem powerless” and “hunches no longer pass for evidence these days, unless we’re talking about government policy.” We have compared the policy-making process to a chaotic game of tag and suggested that government policymakers can act as seemingly irrational as Cosmo Kramer did on Seinfeld.

whitePaper | March 16, 2022

A long-term commitment to sustained federal research and development (R&D) funding in AI is critical to advance the United States’ leadership in global innovation. The federal government should increase non-defense investment in AI and basic research to strengthen research in critical fields of AI R&D, including healthcare, education, finance, and more, that underpin economic stability and robust growth. Such investment should reflect a multidisciplinary approach, focused on advancing basic and applied R&D, research on AI governance and norm-setting, and supporting research infrastructure with multi-agency collaboration.

whitePaper | March 3, 2020

Artificial intelligence (AI) systems have raised concerns in the public—some speculative and some based in contemporary experience. Some of these concerns overlap with concerns about privacy of data, some relate to the effectiveness of AI systems and some relate to the possibility of the misapplication of the technology. At the same time, the development of AI technology is seen as a matter of national priority, and fears of losing the “AI technology race” fuel national efforts to support its development.